Systemic Sclerosis-associated Interstitial Lung Disease

Also known as: Systemic Sclerosis Associated Interstitial Lung Disease / Systemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD) / Scleroderma-Associated Interstitial Lung Disease (SSC-ILD) / Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD)

DrugDrug NameDrug Description
DB09079NintedanibA triple angiokinase inhibitor indicated for the treatment of idiopathic pulmonary fibrosis, systemic sclerosis-associated interstitial lung disease, and in combination with docetaxel for non-small cell lung cancer.
DB06273TocilizumabAn interleukin-6 (IL-6) receptor antagonist used to treat Cytokine Release Syndrome (CRS), Systemic Juvenile Idiopathic Arthritis (sJIA), Giant Cell Arteritis (GCA), and Rheumatoid Arthritis (RA).
DrugDrug NamePhaseStatusCount
DB12775Abituzumab2Terminated1
DB08879Belimumab3Recruiting1
DB04951Pirfenidone3Unknown Status1